<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839683</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-036</org_study_id>
    <nct_id>NCT00839683</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase A - To assess the effect of simvastatin on the pharmacokinetics (PK) of dapagliflozin
      and to determine the effect of dapagliflozin on the PK of simvastatin, when simvastatin and
      dapagliflozin are coadministered in healthy subjects. Phase B - To assess the effect of
      valsartan on the PK of dapagliflozin and to determine the effect of dapagliflozin on the PK
      of valsartan, when valsartan and dapagliflozin are coadministered in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs</measure>
    <time_frame>72 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of dapagliflozin when administered alone, with valsartan, or with simvastatin in healthy subjects</measure>
    <time_frame>15 timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of the combination of dapagliflozin with valsartan, and the combination of dapagliflozin with simvastatin in healthy subjects</measure>
    <time_frame>15 timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of dapagliflozin on the PK of simvastatin acid (active metabolite of simvastatin), when coadministered in healthy subjects</measure>
    <time_frame>15 timepoints</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin + simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin + valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Tablets, Oral, 20 mg, Single Dose</description>
    <arm_group_label>simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets, Oral, 20 mg, Single Dose</description>
    <arm_group_label>Dapagliflozin + simvastatin</arm_group_label>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Dapagliflozin + valsartan</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Oral, 40 mg, Single Dose</description>
    <arm_group_label>Dapagliflozin + simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>Tablets, Oral, 320 mg, Single Dose</description>
    <arm_group_label>valsartan</arm_group_label>
    <arm_group_label>Dapagliflozin + valsartan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/[height (m)]2

        Exclusion Criteria:

          -  Women of childbearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period and for up to 12 weeks after the
             last dose of investigational product

          -  Abnormal urinalysis at screening (repeat urinalysis may be allowed for positive
             hematuria in women)

          -  Glucosuria at screening

          -  Abnormal liver functions tests (ALT, AST or total bilirubin &gt; 10% above ULN)

          -  Presence of edema on physical exam

          -  History of diabetes mellitus

          -  History of heart failure

          -  History of renal insufficiency

          -  History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the
             past 3 months

          -  History of recurrent (defined as 3 occurences per year) or recent vulvovaginal mycotic
             infections

          -  Positive urine screen for drugs of abuse either at screening or before dosing

          -  Positive blood screen for hepatitis C antibody, hepatitis C antibody, hepatitis B
             surface antigen, or HIV-1, -2 antibody

          -  History of allergy to SGLT2 inhibitors or related compounds

          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)

          -  History of allergy or intolerance to valsartan or simvastatin (or related compounds)

          -  Prior exposure to dapagliflozin, valsartan or simvastatin within 3 months of Day -1

          -  Exposure to any investigational drug or placebo within 4 weeks of Day -1

          -  Use of any prescription drugs within 4 weeks or over-the-counter acid controllers
             within 2 weeks prior to any study drug administration

          -  Use of any other drugs, including over-the counter medications within 1 week and
             herbal preparations within 2 weeks prior to admission to the study facility

          -  Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months
             of Day -1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mds Pharma Services (Us) Inc.</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3642&amp;filename=MB102-036_redacted%20_CSR%20_synopsis.pdf</url>
    <description>MB102-036_redacted _CSR _synopsis</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

